Browsing by Author "Karadayi, Kursat"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy: Morbidity and Mortality Analysis of Our Patients
    (ORTADOGU AD PRES \& PUBL CO, 2012-01-01) Karadayi, Kursat; Turan, Mustafa; Karadayi, Sule; Alagozlu, Hakan; Kilickap, Saadettin; Buyukcelik, Abdullah; Sarkis, Cihat; Yucel, Birsen; Boztosun, Abdullah; Cetin, Meral; Yilmaz, Abdulkerim; Yanik, Ali; Sen, Metin
    Objective: The purpose of this study was to analyze the morbidity and mortality of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) with closed abdomen technique in the treatment of peritoneal surface malignancies. Material and Methods: Twenty-six patients (8 with ovarian cancer, 7 peritoneal mesothelioma, 6 colorectal cancer, 3 uterine sarcoma, 1 peritoneal carcinoma and 1 with gastric cancer) underwent 27 procedures. Peritonectomy was performed with complete removal of all the involved visceral and parietal peritoneum. HIPEC was performed with the closed abdominal technique using preheated (42.5 degrees C) perfusate for 60 minutes. EPIC was continued for postoperative 5 days. Results: All patients underwent resection of the lesions. Total pentonectomy was performed in 12 patients, while subtotal or partial peritonectomy was carried out in 14 according to the spread of carcinomatosis. Completeness of cytoreduction score of our patients was 0 in 18 patients, 1 in 6 patients and 2 in 2 patients. Major morbidity developed in 7 patients (27\%). CRS+HIPEC+EPIC yielded acceptable morbidity and mortality rates. Of the 26 patients, 20 (77\%) were alive without evidence of disease with a mean follow-up period of 13 6 months. Overall 1 year survival was 60\%. Conclusion: Cytoreductive approach combined with intraperitoneal chemotherapy prolongs survival in selected patients with peritoneal carcinomatosis (PC) with acceptable morbidity and mortality.
  • Thumbnail Image
    Item
    Management of neuroendocrine carcinomas of the breast: A rare entity
    (SPANDIDOS PUBL LTD, 2011-01-01) Yildirim, Yesim; Elagoz, Sahende; Koyuncu, Ayhan; Aydin, Cengiz; Karadayi, Kursat
    Neuroendocrine (NE) carcinoma of the breast is extremely rare and constitutes less than 0.1\% of all breast tumors. Only a few studies are currently available in the literature and a standard approach to treating this tumor has yet to be established. The aim of this study was to apply pathological treatment modalities in clinical practice and to select the most appropriate treatment accordingly. Six female patients were diagnosed with primary NE carcinoma of the breast. The patients underwent modified radical mastectomy with axillary dissection. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies {[}neuron-specific enolase (NSE), chromogranin, synoptophysin, estrogen and progesterone receptor, c-erbB2 and Ki-67]. The results showed that tumor size ranged from 2 to 4.5 cm in diameter. Lymph node metastasis was detected in 4 (67\%) patients. Estrogen and progesterone receptor expression was found in 5 (83\%) patients. None of the patients expressed c-erbB2. Chromogranin was found to be positive in 5 (83\%) patients. Synoptophysin expression was detected in 5 (83\%) patients. NSE was stained in 4 (67\%) patients. An intraductal component was found in 5 (83\%) patients. Lymphovascular invasion was found in 5 (83\%) patients. Adjuvant chemotherapy was administered to patients with a Ki-67 index of >= 10\%. Radiotherapy was administered to 4 (67\%) patients, and 4 (67\%) patients received hormonal therapy. The mean follow-up time was 31.1 months (range 12-52). All 6 patients survived, although following chemotherapy and tamoxifen, the disease progressed in 1 patient who received second-line hormonal therapy. In conclusion, NE carcinoma of the breast is a distinct entity. Management of this rare tumor may include surgery and radiotherapy depending on the size of the tumor and lymph node status. However, the exact role of chemotherapy and hormonal therapy has yet to be established. Adjuvant chemotherapy is recommended for patients with a Ki-67 index of >= 10\%, and hormonal treatment appears to be feasible in patients who are positive for estrogen and/or progesterone receptor.